通脉口服液提取工艺变更及药理试验验证

Extraction Technology Change and Pharmacological Test Verification of Tongmai Oral Liquid

摘要:

目的: 比较不同提取工艺制备的通脉提取液对实验性小鼠心肌缺血的影响。方法: 采用腹腔注射异丙肾上腺素建立小鼠心肌缺血模型,比较不同提取工艺制备的通脉提取液A和通脉提取液B、市售通脉口服液、复方丹参片不同药物对小鼠血浆ATP含量、心肌组织的影响。结果: 模型对照组、通脉口服液组、通脉提取液A组、通脉提取液B组、复方丹参片组、空白正常组血浆中ATP质量浓度分别为(197.06±77.78),(239.60±60.90),(328.21±84.27),(318.42±70.87),(271.13±66.45),(475.93±94.98) μg·L^-1,心肌组织损伤指数分别为(2.26±0.86),(1.16±0.28),(0.59±0.17),(0.76±0.23),(0.68±0.12),0。通脉提取液A和通脉提取液B均表现出比通脉口服液更为显著的治疗效果,治疗效果优于复方丹参片,且通脉提取液A效果略优于通脉提取液B。结论: 变更工艺后制备的通脉提取液A和B均可显著改善小鼠心脏缺血,提高心功能,治疗效果明显优于市售通脉口服液,其中通脉提取液A作用更显著。

Abstract:

Objective: To compare effects of different extraction processes for Tongmai oral liquid on experimental myocardial ischemia in mice. Method: Intraperitoneal injection of isoproterenol in mice to establish model of myocardial ischemia.Effects of Tongmai extract A,Tongmai extract B,commercially available Tongmai oral liquid and compound Danshen tablets on plasmic ATP content and myocardial tissue in mice were compared. Result: The concentration of plasmic ATP in model group,Tongmai oral liquid group,Tongmai extract A group,Tongmai extract B group,compound Danshen tablets group and blank control group were (197.06±77.78),(239.60±60.90),(328.21±84.27),(318.42±70.87),(271.13±66.45),(475.93±94.98) μg·L^-1,respectively;Myocardial tissue damage index of these groups were (2.26±0.86),(1.16±0.28),(0.59±0.17),(0.76±0.23),(0.68±0.12),0,respectively.Treatment effect of Tongmai extract A and Tongmai extract B were significantly better than Tongmai oral liquid and better than compound Danshen tablets without significantly influence,but Tongmai extract A was slightly better than Tongmai extract B. Conclusion: After changing of extraction processes,Tongmai extract A and Tongmai extract B could significantly improve myocardial ischemia in mice by increasing heart function,treatment effect was significantly better than commercially available Tongmai oral liquid,wherein Tongmai extraction A showed more significant role.